LOLivia Onofrio

Livia Onofrio

*This is an algorithmically generated author record based on publicly available information.

Livia Onofrio has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Alberto Signore

    Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, Italy

    1 shared publication
  • Alessandro Palmieri

    Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy

    1 shared publication
  • Amalia Luce

    Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

    1 shared publication
  • Andor W. J. M. Glaudemans

    Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    1 shared publication
  • Antonella Lucia Marretta

    Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy

    1 shared publication
  • Antonio Faiella

    Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

    1 shared publication

Latest Publications

  • Open Access

    The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target

    by Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio

    Background. c-MET is a receptor tyrosine kinase receptor (RTK) for the hepatocyte growth factor (HGF). The binding of HGF to c-MET regulates several cellular functions: differentiation, proliferation, epithelial cell motility, angiogenesis, and epithelial-mesenchymal transition (EMT). Moreover, it is known to be involved in carcinogenesis. Comprehension of HGF-c-MET signaling pathway might have important clinical consequences allowing to predict prognosis, response to treatment, and survival rates based on its expression and dysregulation. Discussion. c-MET represents a useful molecular target for novel engineered drugs. Several clinical trials are underway for various solid tumors and the development of new specific monoclonal antibodies depends on the recent knowledge about the definite c-MET role in each different malignance. Recent clinical trials based on c-MET molecular targets result in good safety profile and represent a promising therapeutic strategy for solid cancers, in monotherapy or in combination with other target drugs. Conclusion. The list of cell surface receptors crosslinking with the c-MET signaling is constantly growing, highlighting the importance of this pathway for personalized target therapy. Research on the combination of c-MET inhibitors with other drugs will hopefully lead to discovery of new effective treatment options.


  • Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

    by Giuseppe Di Lorenzo, Silvia Zappavigna, Felice Crocetto, Mario Giuliano, Dario Ribera, Rocco Morra, Luca Scafuri, Antonio Verde, Dario Bruzzese, Simona Iaccarino, et al.


  • Open Access

    Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy

    by Alberto Signore, Chiara Lauri, Sveva Auletta, Michela Varani, Livia Onofrio, Andor W. J. M. Glaudemans, Francesco Panzuto, Paolo Marchetti

    Molecular medicine has gained clinical relevance for the detection and staging of oncological diseases, to guide therapy decision making and for therapy follow-up due to the availability of new highly sensitive hybrid imaging camera systems and the development of new tailored radiopharmaceuticals that target specific molecules. The knowledge of the expression of different receptors on the primary tumor and on metastases is important for both therapeutic and prognostic purposes and several approaches are available aiming to achieve personalized medicine in different oncological diseases. In this review, we describe the use of specific radiopharmaceuticals to image and predict therapy response in breast cancer and neuroendocrine tumors since they represent a paradigmatic example of the importance of tumoral characterization of hormonal receptors in order to plan a tailored treatment. The most attractive radiopharmaceuticals for breast cancer are 16α-[18F]-fluoro-17β-estradiol for PET assessment of the estrogen expression, radiolabeled monoclonal antibody trastuzumab to image the human epidermal growth factor receptor 2, but also the imaging of androgen receptors with [18F]-fluorodihydrotestosterone.